Biontech Stock – Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents
Vaccine stocks — including BioNTech stock — pared deep losses Thursday after German Chancellor Angela Merkel opposed waiving Covid vaccine patent rights.
This week, the World Trade Organization called for member nations to temporarily easeApple-converted-space”> patent protections for Covid vaccines, like those produced byApple-converted-space”> BioNTech ((BNTX)) andApple-converted-space”> Moderna (MRNA). On Wednesday, President Joe Biden and U.S. Trade Representative Ambassador Katherine Tai voiced support for the move.
But Merkel saidApple-converted-space”> waiving patent protectionsApple-converted-space”> would create “severe complications” for the production of vaccines, Bloomberg reported early Thursday, citing a German government spokeswoman.
In midday trading on theApple-converted-space”> stock market today, BioNTech stock fell 2.8% near 165.90. That was better than an earlier 15% plunge. Moderna stock toppled 3.5% near 157.10. Shares of Moderna were also under pressure afterApple-converted-space”> first-quarter Covid vaccine salesApple-converted-space”> missed forecasts.
BioNTech Stock Under Pressure
Merkel wasn’t alone in her views — bullishly for BioNTech stock.
Dr. Michelle McMurry-Heath, chief executive of industry group Biotechnology Innovation Organization, penned a letter WednesdayApple-converted-space”> opposing the plan. McMurry-Heath is reportedly being considered toApple-converted-space”> head up the U.S. Food and Drug Administration.
“Handing needy countries a recipe book without the ingredients, safeguards and sizable workforce needed will not help people waiting for the vaccine,” she said. “Handing them the blueprint to construct a kitchen that — in optimal conditions — can take a year to build will not help us stop the emergence of dangerous new Covid variants.”
Instead, McMurry-Heath suggested making the U.S. the world’s “arsenal of vaccines.” The suggestion is a quote from Biden just last week.
Vaccine Stocks Expect Big Sales
Waiving Covid vaccine patents would hamstring BioNTech stock and a handful of small biotech companies with a single product either on the market or expected to soon launch.
Moderna and BioNTech use messenger RNA technology in their vaccines. These vaccines tell the body to make a single protein, mimicking a portion of the Covid vaccine. The immune system then makes antibodies. Novavax‘s (NVAX) experimental vaccine uses insect cells.
The former two are already authorized in the U.S. and other countries. Novavax’s vaccine is under a rolling review in the U.S. In the first quarter, Moderna generated $1.73 billion in sales of its Covid vaccine.Apple-converted-space”> Pfizer (PFE), BioNTech’s partner, reported $3.5 billion inApple-converted-space”> vaccine sales.
YOU MAY ALSO LIKE:
Regeneron Edges Higher After Covid Treatment Beats First-Quarter Views
Fido’s Drugmaker Slammed Despite Easy Beat On Growing Pet Sales
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
Options Trading: How To Start Using Options, How To Manage Risk
Short-Term Trades Can Add Up To Big Profits. IBD’s SwingTrader Shows You How